MA50397A - Anticorps anti-tau et leurs utilisations - Google Patents

Anticorps anti-tau et leurs utilisations

Info

Publication number: MA50397A
Authority: MA; Morocco
Prior art keywords: tau; body anti
Prior art date: 2017-10-16

Application number

MA050397A

Other languages

English (en)

Inventor

Kishan Agarwala

Shigeru Akasofu

Hirofumi Aoyagi

Silva Hettihewage Alfred Rohan De

Yutaka Hashizume

Malcolm Ian Roberts

Jared Spidel

James Martin Staddon

Original Assignee

Eisai R&D Man Co Ltd

Ucl Business Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-16

Filing date

2018-10-16

Publication date

2020-08-26

2018-10-16 Application filed by Eisai R&D Man Co Ltd, Ucl Business Ltd filed Critical Eisai R&D Man Co Ltd

2020-08-26 Publication of MA50397A publication Critical patent/MA50397A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

MA050397A 2017-10-16 2018-10-16 Anticorps anti-tau et leurs utilisations MA50397A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201762572910P	2017-10-16	2017-10-16
US201762577011P	2017-10-25	2017-10-25
US201862697034P	2018-07-12	2018-07-12

Publications (1)

Publication Number	Publication Date
MA50397A true MA50397A (fr)	2020-08-26

Family

ID=64100697

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050397A MA50397A (fr)	2017-10-16	2018-10-16	Anticorps anti-tau et leurs utilisations

Country Status (22)

Country	Link
US (4)	US10829547B2 (fr)
EP (1)	EP3697814A1 (fr)
JP (2)	JP6851549B2 (fr)
KR (2)	KR20200058480A (fr)
CN (1)	CN111630064B (fr)
AU (1)	AU2018352308B2 (fr)
BR (1)	BR112020007536A2 (fr)
CA (1)	CA3077247A1 (fr)
CL (3)	CL2020001003A1 (fr)
CO (1)	CO2020005981A2 (fr)
IL (2)	IL273832B (fr)
JO (1)	JOP20200074A1 (fr)
MA (1)	MA50397A (fr)
MX (1)	MX2020003857A (fr)
NZ (1)	NZ762251A (fr)
PE (2)	PE20210115A1 (fr)
PH (2)	PH12020551216A1 (fr)
SG (1)	SG11202003392VA (fr)
TW (3)	TWI809562B (fr)
UA (1)	UA129617C2 (fr)
WO (1)	WO2019077500A1 (fr)
ZA (1)	ZA202001548B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10501531B2 (en)	2013-03-13	2019-12-10	Prothena Biosciences Limited	Tau immunotherapy
MY198194A (en)	2016-05-02	2023-08-09	Prothena Biosciences Ltd	Antibodies Recognizing Tau
PT3452507T (pt)	2016-05-02	2022-12-20	Prothena Biosciences Ltd	Imunoterapia anti-tau
SG11201907422RA (en)	2017-02-17	2019-09-27	Denali Therapeutics Inc	Anti-tau antibodies and methods of use thereof
KR102784294B1 (ko)	2017-05-02	2025-03-19	프로테나 바이오사이언시즈 리미티드	타우 인식 항체
AU2018352308B2 (en) *	2017-10-16	2025-06-05	Eisai R&D Management Co., Ltd.	Anti-tau antibodies and uses thereof
JP7630834B2 (ja)	2019-03-03	2025-02-18	プロセナバイオサイエンシーズリミテッド	タウ認識抗体
US12060434B2 (en) *	2020-02-25	2024-08-13	Gensun Biopharma Inc.	Trispecific T cell engagers
US20220064271A1 (en) *	2020-09-01	2022-03-03	Washington University	Methods for treating tauopathies
KR20230078748A (ko) *	2020-10-02	2023-06-02	일라이 릴리 앤드 캄파니	항체 정제 공정에서의 숙주 세포 단백질 함량을 감소시키는 방법 및 감소된 숙주 세포 단백질 함량을 가지는 항체 조성물
AU2022307687A1 (en)	2021-07-09	2024-01-04	Eisai R&D Management Co., Ltd.	Biomarkers for alzheimer's disease treatment
EP4426336A1 (fr)	2021-11-03	2024-09-11	Eisai R&D Management Co., Ltd.	Compositions d'anticorps anti-tau, formes galéniques et méthodes
US20250034559A1 (en)	2021-11-17	2025-01-30	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
MX2024007288A (es)	2021-12-17	2024-06-28	Eisai R&D Man Co Ltd	Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau.
WO2023111618A1 (fr)	2021-12-17	2023-06-22	Eisai R&D Management Co., Ltd.	Méthodes d'utilisation d'un anticorps anti-amyloïde à protofibrille bêta et d'un anticorps anti-tau
AU2022439338A1 (en)	2022-02-02	2024-08-15	Eisai R&D Management Co., Ltd.	Methods of treatment using p-tau181 level
KR20250069606A (ko)	2022-09-15	2025-05-19	보이저 테라퓨틱스, 인크.	타우 결합 화합물
JP2025539394A (ja)	2022-11-28	2025-12-05	エーザイ・アール・アンド・ディー・マネジメント株式会社	タウｐｅｔレベルを使用する治療の方法
KR20260022396A (ko)	2023-06-09	2026-02-19	에자이 알앤드디 매니지먼트 가부시키가이샤	항-Aβ 프로토피브릴 항체를 사용한 치료 방법
WO2025019457A1 (fr)	2023-07-15	2025-01-23	Eisai R&D Management Co., Ltd.	Peptides antimicrobiens
WO2025122634A1 (fr)	2023-12-05	2025-06-12	Voyager Therapeutics, Inc.	Compositions et méthodes pour le traitement de troubles liés à la protéine tau
WO2025137359A1 (fr)	2023-12-20	2025-06-26	Eisai R&D Management Co., Ltd.	Procédés de dosage servant à identifier une maladie
WO2025198916A1 (fr) *	2024-03-16	2025-09-25	Abbvie Inc.	Anticorps anti-tau
WO2026015877A1 (fr)	2024-07-12	2026-01-15	Eisai R&D Management Co., Ltd.	Biomarqueur fluide

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7501121B2 (en)	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
HUE026846T2 (en)	2007-12-18	2016-08-29	Bioalliance Cv	Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use
UA107571C2 (xx)	2009-04-03	2015-01-26		Фармацевтична композиція
CN106390107B (zh)	2009-06-10	2019-12-31	纽约大学	病理tau蛋白的免疫靶向
US8609097B2 (en)	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
MY164376A (en)	2010-10-07	2017-12-15	Univ Leuven Kath	Phosphospecific antibodies recognizing tau
CA2813493C (fr)	2010-10-11	2019-07-09	University Of Zurich	Anticorps anti-tau humain
WO2012125555A1 (fr)	2011-03-11	2012-09-20	Ramot At Tel-Aviv University Ltd.	Méthode de traitement de tauopathie neurodégénérative
GB201112056D0 (en)	2011-07-14	2011-08-31	Univ Leuven Kath	Antibodies
ME03008B (fr) *	2011-09-19	2018-10-20	Axon Neuroscience Se	Thérapie protéique et diagnostic d'une pathologie à médiation par tau dans la maladie d'alzheimer
MX350311B (es)	2011-12-20	2017-09-01	Janssen Biotech Inc	Anticuerpos anti-phf-tau y sus usos.
RU2644242C2 (ru)	2012-04-05	2018-02-08	Ац Иммуне С.А.	Гуманизированное тау-антитело
WO2013177104A2 (fr)	2012-05-21	2013-11-28	Felder Mitchell S	Traitement de tauopathies
PL2857039T3 (pl)	2012-05-31	2020-05-18	Osaka City University	Środek terapeutyczny lub środek profilaktyczny na otępienie
SG10201708959WA (en) *	2012-07-03	2017-11-29	Univ Washington	Antibodies to tau
NZ630542A (en)	2012-08-16	2017-06-30	Ipierian Inc	Methods of treating a tauopathy
EP2906596B1 (fr)	2012-10-12	2023-12-27	Arizona Board of Regents on behalf of Arizona State University	Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
US9910048B2 (en)	2012-12-03	2018-03-06	Washington University	Method for detection of aggregates in biological samples
CA2896066C (fr)	2012-12-21	2022-07-12	Biogen Ma Inc.	Anticorps anti-tau humains
WO2014096321A1 (fr)	2012-12-21	2014-06-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticorps spécifiques de la protéine tau phosphorylée à la sérine 422 et leurs utilisations pour traiter et diagnostiquer les tauopathies
US10501531B2 (en)	2013-03-13	2019-12-10	Prothena Biosciences Limited	Tau immunotherapy
WO2014150877A2 (fr)	2013-03-15	2014-09-25	Ac Immune S.A.	Anticorps anti-tau et leurs procédés d'utilisation
SG11201509982UA (fr)	2013-06-06	2016-04-28	Igenica Biotherapeutics Inc
BR112015030356A2 (pt)	2013-06-10	2017-12-05	Ipierian Inc	métodos de tratamento de uma taupatia
GB201312226D0 (en)	2013-07-08	2013-08-21	Adx Neurosciences	Improved antibodies
AU2014368696A1 (en)	2013-12-20	2016-06-02	F. Hoffmann-La Roche Ag	Humanized anti-Tau(pS422) antibodies and methods of use
WO2015170528A1 (fr)	2014-05-07	2015-11-12	株式会社村田製作所	Dispositif à ondes acoustiques de surface
BR112016029579A2 (pt) *	2014-06-26	2017-08-22	Janssen Vaccines & Prevention Bv	anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
AR100978A1 (es)	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh)	2014-06-27	2021-08-01	美商Ｃ２Ｎ醫療診斷有限責任公司	人類化抗-tau抗體
DE102014013571A1 (de)	2014-09-18	2016-03-24	Aj Roboscreen Gmbh	Monoklonaler Antikörper gegen humanes TAU-Protein
CN107428820B (zh)	2014-11-19	2022-03-22	阿克松神经系统科学公司	在阿尔茨海默氏病中的人源化tau抗体
EP3223689A4 (fr)	2014-11-25	2018-05-02	Abbott Diabetes Care Inc.	Systèmes de surveillance d'analyte et procédés de surveillance et de test associés
WO2016112078A2 (fr)	2015-01-08	2016-07-14	Janssen Biotech, Inc.	Anticorps tau/anti-phf et leurs utilisations
EP3261670A4 (fr)	2015-02-24	2018-08-01	Rpeptide, LLC	Anticorps anti-tau
TWI669314B (zh) *	2015-02-26	2019-08-21	美國禮來大藥廠	針對ｔａｕ之抗體及其用途
NZ775762A (en)	2015-06-05	2025-02-28	Genentech Inc	Anti-tau antibodies and methods of use
WO2017005734A1 (fr)	2015-07-06	2017-01-12	Ucb Biopharma Sprl	Anticorps se liant à tau
US10344081B2 (en)	2015-07-06	2019-07-09	Ucb Biopharma Sprl	Tau-binding antibodies
JO3711B1 (ar)	2015-07-13	2021-01-31	H Lundbeck As	أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US9704904B2 (en) *	2015-08-27	2017-07-11	Taiwan Semiconductor Manufacturing Company, Ltd.	Deep trench isolation structures and methods of forming same
WO2017062496A2 (fr)	2015-10-05	2017-04-13	University Of Virginia Patent Foundation	Anticorps anti-sas1b, procédés d'utilisation associés, et compositions et procédés de détection et de traitement du cancer
US20190330335A1 (en) *	2015-10-06	2019-10-31	Alector Llc	Anti-trem2 antibodies and methods of use thereof
MY198194A (en)	2016-05-02	2023-08-09	Prothena Biosciences Ltd	Antibodies Recognizing Tau
MX2018013386A (es)	2016-05-02	2019-02-28	Prothena Biosciences Ltd	Anticuerpos que reconocen tau.
PH12018502613B1 (en)	2016-07-12	2023-02-01	H Lundbeck As	Antibodies specific for hyperphosphorylated tau and methods of use thereof
SG11201907422RA (en)	2017-02-17	2019-09-27	Denali Therapeutics Inc	Anti-tau antibodies and methods of use thereof
JP2018139530A (ja)	2017-02-27	2018-09-13	帝人ファーマ株式会社	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TWI771389B (zh)	2017-03-16	2022-07-21	美商健生生物科技公司	抗phf-tau抗體及其用途
KR102784294B1 (ko) *	2017-05-02	2025-03-19	프로테나 바이오사이언시즈 리미티드	타우 인식 항체
AU2018352308B2 (en) *	2017-10-16	2025-06-05	Eisai R&D Management Co., Ltd.	Anti-tau antibodies and uses thereof

2018
- 2018-10-16 AU AU2018352308A patent/AU2018352308B2/en active Active
- 2018-10-16 TW TW110142156A patent/TWI809562B/zh active
- 2018-10-16 KR KR1020207011686A patent/KR20200058480A/ko not_active Ceased
- 2018-10-16 US US16/161,586 patent/US10829547B2/en active Active
- 2018-10-16 TW TW107136326A patent/TWI750419B/zh active
- 2018-10-16 MA MA050397A patent/MA50397A/fr unknown
- 2018-10-16 EP EP18796772.4A patent/EP3697814A1/fr active Pending
- 2018-10-16 MX MX2020003857A patent/MX2020003857A/es unknown
- 2018-10-16 PE PE2020000397A patent/PE20210115A1/es unknown
- 2018-10-16 NZ NZ762251A patent/NZ762251A/en unknown
- 2018-10-16 BR BR112020007536-1A patent/BR112020007536A2/pt unknown
- 2018-10-16 WO PCT/IB2018/058024 patent/WO2019077500A1/fr not_active Ceased
- 2018-10-16 UA UAA202002730A patent/UA129617C2/uk unknown
- 2018-10-16 PH PH1/2020/551216A patent/PH12020551216A1/en unknown
- 2018-10-16 CA CA3077247A patent/CA3077247A1/fr active Pending
- 2018-10-16 SG SG11202003392VA patent/SG11202003392VA/en unknown
- 2018-10-16 PE PE2021000519A patent/PE20212088A1/es unknown
- 2018-10-16 TW TW112123476A patent/TWI853617B/zh active
- 2018-10-16 JP JP2020518723A patent/JP6851549B2/ja active Active
- 2018-10-16 CN CN201880066003.1A patent/CN111630064B/zh active Active
- 2018-10-16 KR KR1020207011600A patent/KR102225178B1/ko active Active
- 2018-10-16 JO JOP/2020/0074A patent/JOP20200074A1/ar unknown
- 2018-12-12 US US16/217,360 patent/US10358485B2/en active Active
2020
- 2020-03-11 ZA ZA2020/01548A patent/ZA202001548B/en unknown
- 2020-04-06 IL IL273832A patent/IL273832B/en unknown
- 2020-04-08 PH PH12020550243A patent/PH12020550243A1/en unknown
- 2020-04-15 CL CL2020001003A patent/CL2020001003A1/es unknown
- 2020-05-15 CO CONC2020/0005981A patent/CO2020005981A2/es unknown
- 2020-09-24 US US17/030,655 patent/US11578120B2/en active Active
2021
- 2021-03-02 CL CL2021000516A patent/CL2021000516A1/es unknown
- 2021-03-02 CL CL2021000517A patent/CL2021000517A1/es unknown
- 2021-03-09 JP JP2021037603A patent/JP7223794B2/ja active Active
2022
- 2022-02-21 IL IL290783A patent/IL290783A/en unknown
2023
- 2023-01-04 US US18/149,905 patent/US20240034777A1/en active Pending

Also Published As

Publication number	Publication date
PH12020550243A1 (en)	2021-02-15
NZ762251A (en)	2025-12-19
TW202207985A (zh)	2022-03-01
US20190112364A1 (en)	2019-04-18
US20190112365A1 (en)	2019-04-18
CN111630064A (zh)	2020-09-04
MX2020003857A (es)	2021-01-08
RU2020115817A3 (fr)	2022-04-08
IL290783A (en)	2022-04-01
SG11202003392VA (en)	2020-05-28
KR20200058480A (ko)	2020-05-27
AU2018352308A1 (en)	2020-03-19
IL273832A (en)	2020-05-31
CL2020001003A1 (es)	2020-10-02
CL2021000516A1 (es)	2021-09-24
CL2021000517A1 (es)	2021-09-24
US20240034777A1 (en)	2024-02-01
PH12020551216A1 (en)	2024-06-24
US11578120B2 (en)	2023-02-14
KR102225178B1 (ko)	2021-03-10
CN111630064B (zh)	2023-06-27
ZA202001548B (en)	2021-10-27
CA3077247A1 (fr)	2019-04-25
TWI750419B (zh)	2021-12-21
TWI853617B (zh)	2024-08-21
KR20200051035A (ko)	2020-05-12
JOP20200074A1 (ar)	2020-04-30
AU2018352308B2 (en)	2025-06-05
US10829547B2 (en)	2020-11-10
WO2019077500A1 (fr)	2019-04-25
PE20212088A1 (es)	2021-11-04
RU2020115817A (ru)	2021-11-18
EP3697814A1 (fr)	2020-08-26
BR112020007536A2 (pt)	2020-09-29
UA129617C2 (uk)	2025-06-18
IL273832B (en)	2022-06-01
US10358485B2 (en)	2019-07-23
TW201927817A (zh)	2019-07-16
US20210024622A1 (en)	2021-01-28
TW202340244A (zh)	2023-10-16
JP7223794B2 (ja)	2023-02-16
PE20210115A1 (es)	2021-01-19
JP2021097698A (ja)	2021-07-01
JP6851549B2 (ja)	2021-03-31
CO2020005981A2 (es)	2020-07-31
TWI809562B (zh)	2023-07-21
JP2020536534A (ja)	2020-12-17

Publication	Publication Date	Title
MA50397A (fr)	2020-08-26	Anticorps anti-tau et leurs utilisations
FR24C1023I2 (fr)	2026-04-03	Anticorps thérapeutiques et leurs utilisations
EP3625263A4 (fr)	2021-05-05	Anticorps anti-galectine-9 et leurs utilisations
EP3383916A4 (fr)	2019-09-11	Anticorps anti-cd73 et leurs utilisations
EP3891183A4 (fr)	2022-08-31	Anticorps anti-claudine et leurs utilisations
MA47789A (fr)	2020-01-22	Anticorps anti-phf-tau et leurs utilisations
EP3389702A4 (fr)	2019-08-14	Anticorps anti-lag-3 et leurs utilisations
EP3504243A4 (fr)	2020-03-11	Anticorps anti-tim-3 et leurs utilisations
EP3759143A4 (fr)	2022-03-02	Anticorps anti-tigit et leurs utilisations
MA49683A (fr)	2020-06-03	Anticorps anti-cd8 et leurs utilisations
MA46708A (fr)	2021-05-05	Anticorps anti-pd1 et leurs utilisations
MA49537A (fr)	2020-05-13	Anticorps anti-lag3 et leurs utilisations
MA46704A (fr)	2019-09-11	Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3661965A4 (fr)	2022-07-13	Anticorps anti-cd47 et leurs utilisations
EP3426288A4 (fr)	2019-10-30	Anticorps anti-pacap et leurs utilisations
MA50618A (fr)	2020-08-12	Polyrhérapies et leurs utilisations
MA49886A (fr)	2020-06-24	Anticorps anti-par2 et leurs utilisations
MA53184A (fr)	2021-05-26	Anticorps anti-ox40 et leurs utilisations
MA45235A (fr)	2019-04-17	Anticorps anti-c5 et leurs utilisations
EP3283516A4 (fr)	2019-03-06	Anticorps anti-pacap et leurs utilisations
MA45125A (fr)	2021-06-02	Anticorps anti-alpha-synucléine et leurs utilisations
EP3383904A4 (fr)	2019-12-04	Anticorps ctla-4 et leurs utilisations
EP3645563A4 (fr)	2021-03-17	Anticorps anti-fam19a5 et leurs utilisations
EP3562508A4 (fr)	2021-04-07	Anticorps anti-lair1 et leurs utilisations
MA43567A (fr)	2018-11-14	Anticorps pacap et leurs utilisations